[ad_1]
WARMINSTER, Pa., March 08, 2024 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop chronic Functional therapeutics for patients with hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will participate in and host the following two upcoming investor conferences in Miami, Florida:
-
Barclays 26th Annual Global Healthcare Conference: Formal presentation will be on March 12, 2024 at 2:05 pm ET
-
Jefferies Bay Biotech Summit: March 13, 2024
To view a live webcast of Barclays’ 26th Annual Global Healthcare Conference Presentations, please visit: https://investor.arbutusbio.com/events-presentations. An archived replay of the webcast will be available for a limited time on the Arbutus website following the event.
About Yangmei
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company that leverages its broad virology expertise to identify and develop novel therapies with unique mechanisms of action that can be combined to treat chronic B. Provides functional cure for patients with hepatitis virus (cHBV)). We believe that the keys to successfully developing a functional cure include inhibiting HBV DNA, reducing surface antigens and enhancing HBV-specific immune responses. Our pipeline of proprietary compounds developed in-house includes the RNAi therapeutic imdusiran (AB-729) and the oral PD-L1 inhibitor AB-101. Imdusiran has generated meaningful clinical data demonstrating its effects on both surface antigen reduction and reawakening of HBV-specific immune responses. Imdusiran is currently undergoing two Phase 2a combination clinical trials. AB-101 is currently being evaluated in Phase 1a/1b clinical trials. For more information, please visit www.arbutusbio.com.
Contact information
Investors and media
Lisa M. Cappellelli
Vice President of Investor Relations
Phone: 215-206-1822
Email: lcaperelli@arbutusbio.com
[ad_2]
Source link
